in the presence of surfactant. The success in producing unnatural natural products with unique biological activity from inactivating the various amino-acid modification enzymes described herein should help in developing a clinically useful new antibiotic.
The 2013 winner of the JA Medal for reviews is for a comprehensive and insightful overview on 'Antibiotics in the Clinical Pipeline in 2011' authored by Mark Butler and Matthew Cooper. 2 In this well-researched paper, the authors not only outline antibiotics in various stages of clinical trials, they also describe the recent history of antibiotics brought to market since 2000. The review begins with a description of the clinical need for new antibiotic drugs and of the drug discovery process, both of which are challenges that new drugs must address and negotiate. The paper presents an accurate snapshot of antibiotic discovery at this juncture: a woefully meager number of compounds in late-stage clinical trials and correspondingly very few approved drugs. This situation has not improved since publication of this review.
The current alarming state of affairs means that we have little in the pipeline to address the growing clinical need for new drugs in the short term. In other words, there are no quick fixes to the problems of resistance on the near horizon. Nevertheless, there is some room for hope, which is another message from this paper. There is a growing interest in the area of antibiotic discovery, in particular in academic and small biotech institutions, and an increasing number of compounds in Phase I and II trials and in preclinical development. The authors' survey shows that natural product and synthetic compounds are roughly equally represented in various stages of development. While most of these are derivatives of known chemical scaffolds already in clinical use, a few are novel structures and this is encouraging. This review nicely describes the state of antibiotic development that is accessible to anyone interested in the area of antibiotic discovery and development and as such is a worthy recipient of the 2014 JA Medal for review.
